SPC
GBT

Sigma Planning Corp’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Sigma Planning Corp’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-7,575
Closed -$298K – 929
2017
Q4 		$298K Buy
+7,575
New +$283K 0.02% 612

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Sigma Planning Corp's GBT Position: Q1 2018 in Review

Sigma Planning Corp sold out of Global Blood Therapeutics, Inc. (GBT) in Q1 2018, closing a stake of 7,575 shares — an estimated $298K sold.

Sigma Planning Corp first reported a position in GBT in Q4 2017 and held it in 1 quarter. The position peaked at $298K in Q4 2017. 176 funds tracked by Wall St. Rank hold GBT as of Q1 2018.

  • Sigma Planning Corp reported no remaining Global Blood Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Sigma Planning Corp sold 7,575 Global Blood Therapeutics, Inc. shares in Q1 2018, an estimated $298K.
  • Sigma Planning Corp first reported a position in Global Blood Therapeutics, Inc. in Q4 2017 and held it in 1 quarter.
  • Sigma Planning Corp's Global Blood Therapeutics, Inc. position peaked at $298K in Q4 2017.
  • 176 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q1 2018.

Based on Sigma Planning Corp's 13F filing for Q1 2018, filed 11 May 2018.